CIFoundry

AI tools for heart failure

AI tools that detect heart failure or cardiomyopathy earlier, for example from ECGs or echocardiograms, or that help manage patients already diagnosed.

What the public record shows (updated November 2026): CIFoundry lists 12 tools whose own listing mentions heart failure. Of these, 4 name health-system users, 4 link to a published study and 8 list FDA authorization.

Listed A–Z. We don’t rank tools or recommend vendors, and no one can pay to appear.

Well-documented heart failure tools

Not a ranking. Shown A–Z.

How we picked these

Tools are picked automatically from four public signals recorded in each listing: FDA clearance, De Novo or approval; health systems named as users in news reports; a linked published study; and Epic integration. A tool needs at least 2 of the 4 to appear. Tools with more signals, then more reported health-system users, come first, until about 8 are shown. Tools that tie are shown together or not at all (never more than 10), so no tool is picked over another by name. “Well-documented” describes the public record, not clinical quality. This list is based on information recorded in each listing; a tool's absence doesn't mean it lacks these qualities. No one can pay to appear here, and advertising never affects this list.

All 12 tools

Listed A–Z. Listing is free, and no one can pay to change the order.

Cardiology
FDA Cleared

Anumana ECG-AI LEF (Low Ejection Fraction)

Anumana, Inc. (in partnership with Mayo Clinic)

Anumana ECG-AI LEF is an FDA 510(k)-cleared software-as-a-medical-device that applies a deep learning algorithm to a standard 12-lead ECG to screen for low left ventricular ejection fraction (LVEF <= 40%), a key indicator of heart failure. Developed with Mayo Clinic and trained on over 100,000 ECG-echocardiogram pairs, it achieved an AUROC of 0.92 (84.5% sensitivity, 83.6% specificity) in multisite validation. In the pragmatic EAGLE randomized trial it improved diagnosis of low EF by ~31% without increasing overall echocardiography use. Anumana has since added FDA-cleared 12-lead ECG algorithms for pulmonary hypertension (K252360, March 2026) and cardiac amyloidosis (K253801, April 2026).

  • FDAon record
  • Epicnot on record
  • Named userson record
  • Studyon record
ECGdeep learningheart failure+4

Questions to ask about heart failure tools

  • What input does it use: ECG, echo, remote monitoring or EHR data?
  • What is the follow-up pathway when it flags a patient?
  • What does the published evidence show about outcomes, not just accuracy?

For the full checklist, see the evaluation guides.

How tools are matched

A tool appears here when its own listing (name, description or tags) mentions one of these terms: heart failure, cardiomyopathy, low ejection fraction. A tool that helps with heart failure but doesn’t say so in its listing won’t appear yet. Spot a tool that’s missing or doesn’t belong? Use “Request a correction” on the tool page, or email [email protected], or see how we list tools.

Get weekly updates for Cardiology

Up to 5 new items a week: new tools, FDA decisions and studies. Newest first, never ranked. Confirm by email, unsubscribe any time.

Other conditions